Delcath Systems Inc (DCTH)

[Rapture2020]

RES IPSA LOQUITUR


DCTH IS TELEGRAPHING

Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories

“We are particularly pleased to be working with a supplier of Tillomed’s caliber and experience as it establishes firm control over our melphalan supply chain in Europe and, over time, will provide economies of scale", noted Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.

ECONOMIES OF SCALE: A proportionate saving in costs gained by an increased level of production.

Read: Additional supply is needed to match the increased demand for the CHEMSAT therapy.

http://delcath.com/investors-news/

------------------------------------------------------------------------

Delcath Systems Offers Significant Upside For Risk-Tolerant Investors

Delcath Systems is developing unique, proprietary medical products which are aimed at treating the unmet needs of patients with liver cancer.

There has been significant regulatory and commercial progress in Europe as well as substantial clinical trial progress in the United States.

Recently released clinical data has provided shareholders with renewed optimism.

Significant potential upside awaits investors who are willing to tolerate the risk associated with this investment.

Delcath Systems (DCTH) offers tremendous potential upside for investors who are willing to tolerate a high degree of risk. Shareholders stand to reap a financial windfall if the company manages to successfully navigate clinical, regulatory, and financial hurdles. Delcath Systems' rock-bottom share price provides investors with the opportunity to initiate a large position in the company and take advantage of this uniquely asymmetric risk/reward opportunity.

https://seekingalpha.com/article/4086621-delcath-systems-offers-significant-upside-risk-tolerant-investors

-----------------------------------------------------------------------

Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:

This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”

http://delcath.com/reuters-news/?id=2330074

---------------------------------------------------------------------

Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology

The study authors further concluded that “results clearly demonstrate that PHP Therapy appears to be an effective means of obtaining rapid intrahepatic disease control, and is a sensible option in patients with predominant liver disease.” Researchers said their results support the use of PHP Therapy in an integrated approach to the management of metastatic ocular melanoma, and looked to the company’s Phase 3 FOCUS Trial to further quantify the benefit and optimize treatment strategies for these patients.

https://www.otcmarkets.com/stock/DCTH/news/Positive-Results-From-a-Multi-Center-Analysis-of-Delcath-PHP-Therapy-Published-in-Journal-of-Surgical-Oncology?id=179899

------------------------------------------------------------------------

Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial

“The DSMB’s recommendation to proceed without modification with the FOCUS Trial as planned confirms our own observations of the safety profile of PHP therapy based on prior research and our commercial experience with CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. “Importantly, this initial independent evaluation of the safety profile of melphalan/HDS used the Generation Two filter configuration of the device and the current version of the procedure protocol, and so provides confidence in both our product and procedure. Given that safety concerns with the previous generation product and procedure were the primary issue in the FDA’s previous assessment, we are pleased to have successfully passed this important milestone.

http://delcath.com/reuters-news/?id=2323336

------------------------------------------------------------------------


Delcath Announces Third Quarter 2017 Financial Results

Highlights from the third quarter of 2017 and recent weeks include:
• Revenue for the third quarter of 2017 increased 75% to $0.7 million from $0.4 million in the prior-year quarter;
• Revenue for the first nine months of 2017 increased 53% to $2.0 million from $1.3 million in the prior-year period;
• Medical University of Hannover achieved its 100th CHEMOSAT treatment milestone; over 450 commercial CHEMOSAT procedures have been performed in Europe;
• Positive results from a single institution study of CHEMOSAT filtration efficiency were presented at 2017 CIRSE annual meeting in September

http://delcath.com/reuters-news/?id=2317164

------------------------------------------------------------------------

Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Simon Pedder, Ph.D., a scientist and pharmaceutical executive with a greater than 30-year career in drug development, has joined the Delcath Board of Directors effective November 14, 2017.

Dr. Pedder currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche.

http://delcath.com/reuters-news/?id=2317872

Delcath Announces Satisfaction of 2016 Convertible Note

DCTH is now debt free.

http://delcath.com/investors-news/

------------------------------------------------------------------------